Evaluation of Retinal Nerve Fiber Layer and Macular Thickness Pre- and Post-Chemotherapy With Carboplatin and Paclitaxel in Patients With Endometrial and Ovarian Cancer
- PMID: 37746413
- PMCID: PMC10513924
- DOI: 10.7759/cureus.43943
Evaluation of Retinal Nerve Fiber Layer and Macular Thickness Pre- and Post-Chemotherapy With Carboplatin and Paclitaxel in Patients With Endometrial and Ovarian Cancer
Abstract
Background Carboplatin and paclitaxel are two standard chemotherapeutic agents known to cause neurotoxicity. In this study, we aim to evaluate the toxicity of these agents by measuring the peripapillary retinal nerve fiber layer (RNFL) and macular thickness in patients with endometrial and ovarian cancers who are receiving them. Methods A one-year prospective cohort study involving 28 patients who were treated intravenously with carboplatin (200-400 mg/m2) and paclitaxel (175 mg/m2) three-weekly for six cycles was conducted. RNFL and macula thickness were measured using optical coherence tomography (OCT) before the commencement of chemotherapy, after the third cycle, and one month after the sixth cycle. The main outcome measurements were the average RNFL thickness and central subfield thickness of the macula. Results The mean age of the 28 participants was 54.68 years old (standard deviation [SD] 9.03). Eleven had endometrial cancer, while 17 had ovarian cancer. The mean of the average RNFL thickness during baseline pre-chemotherapy was 96.43 µm (SD 11.39). One month after cessation of treatment, the mean RNFL thickness increased to 101.57 µm (SD 13.54). Statistical analysis showed a significant increment in the mean RNFL thickness (p ≤ 0.001), from baseline to after three cycles, and baseline to one month after six cycles of chemotherapy, except the nasal quadrant. The increment of all macular quadrants was statistically significant (p < 0.05) except for central subfield thickness. Conclusion Systemic administration of carboplatin and paclitaxel affected both the peripapillary RNFL and macula thickness. This represents early evidence of subacute subclinical retinal toxicity. OCT can be used as a screening tool to assess peri-chemotherapeutic retinal alterations.
Keywords: carboplatin; macular thickness; ocular toxicity; paclitaxel; retinal nerve fiber layer.
Copyright © 2023, Chin et al.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures


Similar articles
-
Assessment of ocular neurotoxicity in patients treated with systemic cancer chemotherapeutics.Cutan Ocul Toxicol. 2014 Mar;33(1):7-10. doi: 10.3109/15569527.2013.787087. Epub 2013 May 2. Cutan Ocul Toxicol. 2014. PMID: 23638802 Clinical Trial.
-
Short-term effect of macular edema on the peripapillary retinal nerve fiber layer in patients with wet age-related macular degeneration and diabetic macular edema: A comparative study.Photodiagnosis Photodyn Ther. 2023 Jun;42:103602. doi: 10.1016/j.pdpdt.2023.103602. Epub 2023 May 9. Photodiagnosis Photodyn Ther. 2023. PMID: 37169170
-
Optical tomography-measured retinal nerve fiber layer thickness in normal latinos.Invest Ophthalmol Vis Sci. 2003 Aug;44(8):3369-73. doi: 10.1167/iovs.02-0975. Invest Ophthalmol Vis Sci. 2003. PMID: 12882783
-
Evaluation of macular and peripapillary choroidal thickness, macular volume and retinal nerve fiber layer in acromegaly patients.Int Ophthalmol. 2018 Apr;38(2):617-625. doi: 10.1007/s10792-017-0500-z. Epub 2017 May 15. Int Ophthalmol. 2018. PMID: 28508245
-
Peripapillary retinal nerve fiber layer thickness in a population of 6-year-old children: findings by optical coherence tomography.Ophthalmology. 2006 Sep;113(9):1583-92. doi: 10.1016/j.ophtha.2006.02.067. Ophthalmology. 2006. PMID: 16949443
References
-
- BGCS uterine cancer guidelines: recommendations for practice. Sundar S, Balega J, Crosbie E, et al. Eur J Obstet Gynecol Reprod Biol. 2017;213:71–97. - PubMed
-
- British Gynaecological Cancer Society (BGCS) epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines: recommendations for practice. Fotopoulou C, Hall M, Cruickshank D, et al. Eur J Obstet Gynecol Reprod Biol. 2017;213:123–139. - PubMed
-
- Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders. Agustoni F, Platania M, Vitali M, et al. Cancer Treat Rev. 2014;40:197–203. - PubMed
LinkOut - more resources
Full Text Sources